Release Date: December 23, 2025
Expiration Date: December 23, 2026
Activity Overview
This Burst CME is a video-based program in which expert faculty present and discuss the latest in the diagnosis and management of lupus nephritis (LN). The content focuses on updated guidelines for screening and treatment of lupus nephritis, comparative analyses of current treatments, and clinical trial results for a recently approved therapy. This unique format is designed to accommodate the busy clinician and provide a quick, go-to resource on the topic.
Target Audience
This educational activity is directed toward rheumatologists,
nephrologists, nurse
practitioners, and physician assistants.
Other clinicians involved in the diagnosis and care of LN are also invited to participate.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Identify when to evaluate patients with systemic lupus erythematosus for LN
- Describe the underlying pathogenesis of LN that has led to the investigation of targeted therapies
Michelle Petri, MD, MPH
Professor
Johns Hopkins University School of Medicine
Department of Medicine
Division of Rheumatology
Baltimore, MD
Advisor, Consultant, Grant/ Research Funding: AbbVie, Alexion, Amgen,
Annexon Bio, Architect Therapeutics, Arthros-FocusMed, Astellas, Atara
Biosciences, Autolus, Bain Capital, Baobab Therapeutics, Bavarian Nordic, BioCryst,
Biogen, Boehringer Ingelheim, Boxer Capital, Bristol Myers Squibb, Cabaletta Bio,
Caribou Biosciences Inc, CTI Clinical Trial and Consulting Services, Cullgen,
CVS Health, DualityBio, Enexa Bio,
Exo Therapeutics, Genentech, GentiBio, GSK, iCell Gene Therapeutics, Merck/EMD
Serono, Nexstone Immunology, Novartis, Owkin, PPD Development, Precision
Biosciences, Proviant Therapeutics, Regeneron Pharmaceuticals, Santa Ana Bio,
Seismic Therapeutics, Senti Biosciences, SinoMab Bioscience, Steritas, Takeda,
Tenet Medicines Inc, TG Therapeutics, UCB, Variant Bio, Worldwide Clinical
Trials, Zenas Biopharma
Shivani Garg, MD, PhD
Associate Professor
Director of UW Lupus and Lupus Nephritis Program
University of Wisconsin, School of Medicine and Public Health
Madison, WI
Shivani Garg, MD, PhD, has no relevant financial relationships with ineligible companies.
The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.